ONC submitted a Form 144 reporting the proposed sale of 1,328 ADS on 05/13/2026 following an exercise of stock options. The filing also discloses prior Rule 10b5-1 sales of 332 ADS on 04/08/2026 for $103,447.88 and 341 ADS on 03/11/2026 for $102,300.00.
BeOne Medicines Ltd. filed a post-effective Form S-3 shelf registration to replace an expiring registration, registering up to 398,880,905 Ordinary Shares, including 374,373,961 Ordinary Shares represented by 28,797,997 ADSs (each ADS = 13 Ordinary Shares). The prospectus states BeOne is not selling any shares here and will not receive proceeds; proceeds, if any, will go to the listed selling shareholders. The registration covers resale by Amgen, entities affiliated with Baker Bros. Advisors and HHLR Advisors under existing registration rights. The filing notes cross‑listings on HKEx, Nasdaq and the STAR Market and highlights business, liquidity and China‑related operational risk disclosures incorporated by reference.
BeOne Medicines Ltd. files a new shelf registration on Form S-3 to replace an expiring registration and permit, from time to time, primary offerings and resales of ordinary shares, ADSs, preferred shares, debt securities, warrants and units.
The shelf contemplates offerings by the company and selling shareholders, with proceeds to the company disclosed only in future prospectus supplements; the company discloses key context figures including $731 million in cash and cash equivalents as of March 31, 2026, approximately 1,540,975,898 Registered Shares issued, and recent product and pipeline highlights (BRUKINSA sales of $3.9 billion in 2025). The registration replaces an earlier S-3 that would expire on May 9, 2026.
BeOne Medicines Ltd. reported Q1 2026 revenue of $1.51B, up 35.5% from a year earlier, driven mainly by strong growth in BRUKINSA and TEVIMBRA. Net income rose sharply to $227.4M, compared with near breakeven a year ago, as higher sales and improved gross margin outpaced increased R&D and commercial spending.
Product revenue reached $1.49B, led by BRUKINSA at $1.09B (up 38.3%) and steady growth in Amgen-partnered products. Gross margin improved to 88.8% on a richer mix of BRUKINSA and efficiency gains. Operating cash flow climbed to $201.3M, lifting cash, cash equivalents and restricted cash to $4.85B, while total debt stood at $1.08B and the IMDELLTRA royalty financing liability at $904.4M.
BeOne Medicines reported a very strong first quarter of 2026, with total revenue of $1.51 billion, up 35% from the prior year. Net product revenue was $1.49 billion, driven mainly by oncology medicines.
Flagship BTK inhibitor BRUKINSA generated global sales of $1.1 billion, up 38%, including U.S. sales of $761 million (up 35%). TEVIMBRA reached $206 million in global sales, while Amgen in-licensed products contributed $142 million.
GAAP income from operations rose to $249.9 million and GAAP net income to $227.4 million, compared with nearly break-even a year earlier. GAAP diluted earnings were $1.96 per ADS, and non‑GAAP diluted earnings were $3.24 per ADS. Free cash flow improved to $160.5 million from negative levels.
The company raised full‑year 2026 guidance, now expecting total revenue of $6.3 billion–$6.5 billion and GAAP operating income of $750 million–$850 million. Management highlighted a broad oncology pipeline with multiple late‑stage milestones and regulatory decisions anticipated through 2026–2027.
BeOne Medicines Ltd. has released its 2026 proxy statement for the June 11, 2026 annual general meeting in Zurich, outlining 20 governance, compensation and capital-authorization proposals. Management highlights 2025 as a transformational year, with the company achieving GAAP profitability for the first time and generating meaningful cash flow.
The letter to shareholders emphasizes BeOne’s growing oncology franchise, led by BTK inhibitor BRUKINSA, which delivered $3.9 billion in 2025 global revenue, up 49% year over year. The company reports more than two million patients treated with its medicines and a workforce of nearly 12,000 employees across six continents.
Shareholders are asked to approve Swiss statutory financial statements, carry forward a Swiss standalone accumulated loss of $7.64 million, discharge directors and executives from liability under Swiss law, elect or re-elect ten directors, and ratify Ernst & Young entities as auditors. Additional resolutions seek say-on-pay approvals, updated equity plans, a mandate to issue up to 20% of issued shares, a 10% share repurchase mandate, and an authorization to allocate shares to Amgen to maintain its ownership percentage in future offerings.
Baker Bros. Advisors and affiliates report an 8.0% beneficial ownership stake in BeOne Medicines Ltd. (formerly BeiGene Ltd.) through ordinary shares and American Depositary Shares. The main adviser entities each report 115,462,653 Ordinary Shares, while Julian and Felix Baker each report 115,918,313 Ordinary Shares.
The filing notes BeOne’s redomiciliation to Switzerland and name change, and confirms that each ADS represents thirteen Ordinary Shares. It also discloses that Felix J. Baker has been nominated to serve as a director and Lead Director, while two existing Baker-affiliated directors are not standing for re-election. The Baker-managed funds state they hold their position for investment purposes but may increase or decrease holdings over time.
BeOne Medicines Ltd. files a preliminary proxy statement for its 2026 Annual General Meeting and asks shareholders to vote on 20 proposals, including approval of its audited Swiss statutory standalone and consolidated financial statements and elections to the Board. The letter highlights that BeOne achieved GAAP profitability in 2025 and reported $3.9 billion in global BRUKINSA revenues, a 49% increase versus the prior year. The company states more than 2 million patients have been treated with its medicines, a workforce of approximately 12,000, and a pipeline with late-stage programs (sonrotoclax, BGB-16673) and anticipated regulatory milestones in H1 2026 and 2027.
BeOne Medicines Ltd. furnished additional 2025 financial details tied to its STAR Market annual report, reconciling PRC GAAP disclosures to U.S. GAAP. Revenue for the year ended December 31, 2025 was $5,343,033 thousand, up from $3,810,241 thousand in 2024, with China contributing $1,679,531 thousand and ex-China $3,663,502 thousand.
The gross profit margin ratio was 66.6% in China and 97.0% ex-China for 2025. Total research and development expenses reached $2,145,868 thousand in 2025 versus $1,953,295 thousand in 2024, driven by key programs such as BRUKINSA, TEVIMBRA, sonrotoclax, BGB-16673 and other projects. The company also reported 6,268,800 vials of key products produced or purchased in 2025, with 5,996,100 vials sold and 2,912,600 vials in stock as of year-end.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.